10/2020 |
Series B |
|
$150M |
Taikang Insurance
Haier Medical
Longmen Investment
Softbank China
Sinopharm Zhongjin
|
3/2019 |
Series C |
|
$89.1M |
Softbank China Venture Capital
CMB International Capital
|
6/2018 |
Venture Round |
|
- |
|
3/2019 |
Series C |
3 |
$89M |
China Capital Investment Group
SBCVC
Sinopharm Capital
China Capital Investment Group
SBCVC
Sinopharm Capital
|
6/2021 |
Private Equity Round |
|
$0 |
Redview Capital
Summer Capital
TPG Capital Asia
Valliance Capital
Yingke Capital
Redview Capital
Summer Capital
TPG Capital Asia
Valliance Capital
Yingke Capital
|
6/2016 |
Series A |
|
$45.5M |
|
10/2020 |
Series B |
|
$0 |
Taikang Life Insurance
Beijing Zhongguancun Longmen investment
CMB International Capital Corporation
Haier
Sinopharm Capital
Softbank China &a; India Holdings
Taikang Life Insurance
Beijing Zhongguancun Longmen investment
CMB International Capital Corporation
Haier
Sinopharm Capital
Softbank China &a; India Holdings
|
12/2016 |
Series A |
1 |
$43.6M |
Tongdaoo Capital
Tongdaoo Capital
|
1/2018 |
Series B |
1 |
- |
SBCVC
SBCVC
|
6/2018 |
Venture Round |
|
- |
SoftBank China
SoftBank China
|
6/2021 |
Private Equity Round |
5 |
$220M |
Redview Capital
Summer Capital
TPG Capital Asia
Valliance Capital
Yingke Capital
Redview Capital
Summer Capital
TPG Capital Asia
Valliance Capital
Yingke Capital
|
10/2020 |
Series B |
6 |
$149.8M |
Beijing Zhongguancun Longmen investment
CMB International Capital Corporation
Haier
Sinopharm Capital
Softbank China &a; India Holdings
Taikang Life Insurance
Beijing Zhongguancun Longmen investment
CMB International Capital Corporation
Haier
Sinopharm Capital
Softbank China &a; India Holdings
Taikang Life Insurance
|
3/2019 |
Series C |
3 |
$89M |
China Capital Investment Group
SBCVC
Sinopharm Capital
China Capital Investment Group
SBCVC
Sinopharm Capital
|
1/2018 |
Series B |
1 |
- |
SBCVC
SBCVC
|
12/2016 |
Series A |
1 |
$43.6M |
Tongdaoo Capital
Tongdaoo Capital
|